7 results
In this study we will assess the effect of ARA290 on nerve damage by taking 4 skin bipsies during treatment.
To measure the plasma conc. of ARA 290 in healthy volunteers
ARA290 is a new drug against neuropathic pain and was succesfully tested in previous studies on patients with neuropathic pain due to diabetes and sarcoidosis. The current study involves sarcoidosis patients with pain due to neuropathy. The purpose…
The first aim of the study is to investigate whether DCS addition to exposure therapy enhances symptom reduction in PD+AGO. The second objective of the study is to establish the optimal timing of administration of DCS (30 minutes before or directly…
To assess the analgesic effect of ARA290 in chronic pain patients
To measure the PK of ARA290 when given in de SQ form
The purpose of this phase Ib study is to determine the maximum tolerated dose (MTD) of i.v. and oral panobinostat when given in combination with trastuzumab and paclitaxel. Additional patients will be enrolled at the MTD to further evaluate the…